Company: PRGO
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0001585364-25-000056
Chunk: 284

Company: PERRIGO Co plc
Filing Date: 2025-05-07
Form: 10-Q
Item: Part II, Item 7
Chunk 284
---
 49.6 (1.0)(2.0)%Women's Health15.0 27.2 (12.1)(44.9)%Vitamins, Minerals, and Supplements ("VMS")1.6 4.2 (2.6)(61.9)%Other CSCA0.8 1.4 (0.6)(42.9)%Total CSCA$620.7 $644.1 $(23.4)(3.6)%

Sales in each category were driven primarily by:

•Upper Respiratory: Net sales of $137.9 million increased 5.8% due primarily to higher incidence levels of cough cold compared to the prior year quarter and higher net sales of the allergy products Nasonex®, Triamcinolone Acetonide and Fluticasone. This growth was partially offset by previously disclosed net lost distribution of lower margin products. 

•Nutrition: Net sales of $104.8 million increased 15.7% due primarily to a 19% increase in net sales of infant formula products driven by continuing store brand infant formula business recovery partially offset by lower net sales in contract manufacturing and lower Good Start® brand sales to Canadian customers. 

•Digestive Health: Net sales of $103.0 million decreased 15.7% due primarily to previously disclosed net lost distribution of lower margin products in U.S. Store Brand and lower consumption of proton pump inhibitors, including Omeprazole, Esomeprazole and Lansoprazole, despite Perrigo share gains. These impacts more than offset higher net sales of Polyethylene Glycol. 

•Pain and Sleep-aids: Net sales of $76.6 million decreased 7.3% due primarily to previously disclosed net lost distribution of lower margin products partially offset by new business awards. 

•Healthy Lifestyle: Net sales of $70.4 million decreased 1.3% due primarily to lower category consumption of nicotine replacement therapy products, despite new distribution and market share gains. 

•Oral Care: Net sales of $62.0 million decreased 4.2% due to lower distribution at specific retail customers and lower net sales of Plackers® dental flossers, partially offset by higher net sales of store brands, particularly toothbrushes and flossers. 

•Skin Care: Net sales of $48.6 million decreased 2.0% as growth in the Minoxidil franchise